Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of EOI Foam in Balloon-Occluded Retrograde Transvenous Obliteration (BRTO)
jRCTs031240085Phase 2Recruiting
- Sponsor
- Chiba University Hospital Startup Support Fund
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ethanolamine oleate + iopamidol in Portal Hypertension (PH) (2 arms), sponsored by Chiba University Hospital Startup Support Fund. Primary endpoint: Primary: Ratio of 5% EOI volume to contrast volume used for shunt delineation. Started Sep 2024; status: recruiting.
02
Drugs
ethanolamine oleate + iopamidol
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on jRCTs031240085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240085.